Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: Multicenter, open-label, observational study in Germany

Current Medical Research and Opinion

Volumn 25, Issue 4, 2009, Pages 1003-1009

  Thelen, Ulrich ^a   Buchholz, Patricia ^b   Kimmich, Friedemann ^a  

^a Allergan Europe ^*  (Germany)

^b Eyecons   (Germany)

Author keywords

Alpha agonist; Beta adrenergic inhibitor; Drug combination

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE PLUS TIMOLOL; CARBONATE DEHYDRATASE INHIBITOR; PROSTAGLANDIN DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE IRRITATION; FEMALE; GERMANY; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN ANGLE GLAUCOMA; OPEN STUDY; OPTIC NERVE LESION; QUESTIONNAIRE; RATING SCALE; RISK FACTOR; VISUAL FIELD DEFECT;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; QUINOXALINES; TIMOLOL; VISUAL FIELDS; YOUNG ADULT;

EID: 67649354663     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902805916     Document Type: Article

References (19)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-267 (Pubitemid 43325451)
2. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-440
3. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-1279 (Pubitemid 36105431)
4. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-713 (Pubitemid 34620348)
5. Leske MC, Heijl A, Hyman L, et al. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol 2004;15:102-106 (Pubitemid 38457128)
6. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999;127:20-26 (Pubitemid 29036611)
7. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 1998;105:1960-1967 (Pubitemid 28509740)
8. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997;115:847-852
9. Neufeld AH, Bartels SP, Liu JH. Laboratory and clinical studies on the mechanism of action of timolol. Surv Ophthalmol 1983;28(Suppl):286-292 (Pubitemid 14197377)
10. Munk SA, Harcourt DA, Arasasingham PN, et al. Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem 1997;40:18-23 (Pubitemid 27027261)
11. Larsson LI. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination. Arch Ophthalmol 2001;119:492-495 (Pubitemid 32290057)
12. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999;128:8-14 (Pubitemid 29315757)
13. Lai RK, Chun T, Hasson D, et al. Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci 2002;19:175-185 (Pubitemid 35230993)
14. Ahmed FA, Hegazy K, Chaudhary P, et al. Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res 2001;913:133-139
15. Kim HS, Chang YI, Kim JH, et al. Alteration of retinal intrinsic survival signal and effect of alpha2-adrenergic receptor agonist in the retina of the chronic ocular hypertension rat. Vis Neurosci 2007;24:127-139 (Pubitemid 47093971)
16. Ahmed I. CEED II: an in-depth look at the latest findings. Clin Surg J Ophthalmol 2007;25:1-5
17. Crichton A. Timolol/brimonidine combination therapy in glaucoma management. Clin Surg J Ophthalmol 2005;23:356-359 (Pubitemid 41597481)
18. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230-1238 (Pubitemid 44379855)
19. Goni FJ. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15:581-590 (Pubitemid 41426417)